<DOC>
	<DOCNO>NCT00257920</DOCNO>
	<brief_summary>The purpose study evaluate effect Zemplar® Injection Hectorol® Injection intestinal calcium absorption Chronic Kidney Disease Stage 5 subject hemodialysis .</brief_summary>
	<brief_title>A Study Zemplar® Injection Hectorol® Injection Intestinal Absorption Calcium Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Subject &gt; = 20 year age . Subject diagnose CKD Stage 5 , must maintenance ( chronic ) hemodialysis ( HD ) three time week least 2 month prior Screening Visit expect remain HD duration study . If female , subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : Condoms , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) Contraceptives ( oral parenteral ) three month prior study drug administration In monogamous relationship vasectomize partner If female , subject breastfeed negative serum pregnancy test prior treatment phase . Subject intact PTH value &gt; 200 pg/mL Screening ( Rescreening , applicable ) . Subject serum calcium level &lt; 10.2 mg/dL Screening ( Rescreening , applicable ) . Subject serum phosphorus level &lt; 6.5 mg/dL Screening ( Rescreening , applicable ) . Subject CaxP product &lt; = 65 Screening ( Rescreening , applicable ) . Subject must voluntarily sign date inform consent , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , prior conduct studyspecific procedure . Subject history allergic reaction significant sensitivity vitamin D vitamin D related compound . Subject chronic gastrointestinal disease , Investigator 's opinion , may result clinically significant GI malabsorption . Liver function defect define &gt; 2 time upper limit normal liver enzyme ( SGOT/AST , SGPT/ALT ) level . Subject hemoglobin level &lt; 9.0 g/dL . Subject take maintenance calcitonin , Sensipar® ( cinacalcet ) , glucocorticoids equivalent dose &gt; 5 mg prednisone daily , drug may affect calcium bone metabolism within 2 week prior screen , female stable ( dose product 3 month ) estrogen and/or progestin therapy . For reason , subject consider Investigator unsuitable candidate receive pharmacological dos vitamin D. Subject receive investigational drug within 4 week prior Treatment Phase .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Stage 5 Chronic Kidney Disease ( CKD )</keyword>
</DOC>